Clinical Trials: Psychedelic Therapeutics

Clinical Trials: Psychedelic Therapeutics

Summary

This report provides a review of global psychedelic therapeutic clinical trials derived from the GlobalData’s Clinical Trials Database. The aim of this report is to identify key analyses and segmentations of these trials.

As the number of psychedelic therapeutic clinical trials continues to increase, a deeper understanding of these trials, such as sponsor type, location, and phase, are reviewed.

Scope

• Non-industry sponsors outnumber industry sponsors for psychedelic therapy trials. They account for 58% of psychedelic therapy trials, with the largest margin of difference seen in 2021.
• Yale University is the leading non-industry sponsor while Johnson & Johnson is the leading industry sponsor.
• Central nervous system is by far the top therapy area for psychedelic therapy trials, tested in 92% of all psychedelic therapy trials. The top indication is depression.
• At the country level, the US leads with 88% of all North American studies, followed by China.
• Phase II trials of psychedelic therapies have outnumbered all other phases since 2013.

Reasons to Buy

• Identifies and analyzes psychedelic therapeutic clinical trials by multiple trial designs, such as trial start year, geographic distribution, phase and drug details.
• Examines the cause of the increase of psychedelic clinical trials.
• Gives reasons for certain trends seen in psychedelic trials.
• Breaks down trials by sponsor type and top sponsors.
• Looks at the virtual components used for psychedelic trials.
• Describes the leading drugs used in psychdelic trials.